GHDDI’s Scientific Advisory Board (SAB) Officially Established and Convenes Its First Meeting
On October 17th, 2024, the Global Health Drug Discovery Institute (GHDDI) officially established its Scientific Advisory Board (SAB) and held its first meeting. SAB consists of five leading experts in global health and drug development from both China and abroad, who will provide high-level scientific guidance and strategic advice to GHDDI’s research work.
Dr. Manos Perros, Chairman of the SAB, along with board members Professor Wenhong Zhang and Dr. Yongjun Liu, attended the meeting in person. Professor Kelly Chibale and Professor Zhijian Chen participated remotely.
The establishment of the SAB marks another significant step for GHDDI in promoting international collaborative innovation and exchange to address global health challenges. Under the guidance of the SAB, GHDDI looks forward to accelerating drug discovery, driving innovation, and improving global health outcomes.
